Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been making waves in the biopharmaceutical industry with its strong portfolio of ...
The Associated Press - Business News on MSN15d
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024Copyright 2025 The Associated Press. All Rights Reserved. A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017 ...
OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback